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Introduction:  The  Clinical  and  Laboratory  Standards  Institute  recently  published  M53-A,  Criteria  for  Labo-
ratory  Testing  and  Diagnosis  of  Human  Immunodeﬁciency  Virus  (HIV)  Infection;  Approved  Guideline  (2011),
which  includes  a state  of  the  art algorithm  for identifying  HIV-1  acute  and  HIV-2  infections.  To  assess
the  ability  of Canadian  laboratories  to detect these  sample  types  and  the impact  of M53-A,  the  National
Laboratory  for HIV  Reference  Services  distributed  a special  proﬁciency  testing  panel.
Methods:  HIVS425-2012Nov22  was  sent  to 42  laboratories  across  Canada.  It  contained  one HIV  negative
sample  (B),  two  HIV-1  positive  samples  (A and  E), one  HIV-2  positive  sample  (C)  and one  HIV-1/2  anti-
body  negative-HIV-1  antigen  positive  sample  (D). Data  was  collected  and  analyzed  using  DigitalPT;  a
standardized  on-line  tool.
Results:  Forty-one  laboratories  returned  results.  Sample  B  (HIV  negative)  was  identiﬁed  by 95% of  labo-
ratories  (39/41)  and  samples  A  and  E (HIV-1  positive)  by  98%  (40/41).  No laboratory  identiﬁed  sample
C  as  HIV-2  positive,  although  85% (35/41)  detected  reactivity  prompting  a referral  for further  testing.
The  remaining  laboratories  identiﬁed  sample  C as  HIV-1  positive  (4),  indeterminate  (1)  or  gave no  ﬁnal
status  (1).  Sample  D (HIV  antibody  negative-antigen  positive)  was  correctly  identiﬁed  by two  laborato-
ries  as  HIV-1  antigen  positive  while  78% (32/41)  detected  reactivity,  recommending  further  testing.  One
laboratory  did  not  provide  a ﬁnal  status.  Alarmingly,  six  laboratories  called  this  sample  HIV  negative.
Conclusion:  Although  there  is  a high  quality  of HIV  testing  across  Canada,  introduction  of  the  M53-A
guideline  would  further  improve  the  ability  of laboratories  to  diagnose  HIV-1  acute  and  HIV-2 infection.. Introduction
In December 2011, the Clinical and Laboratory Standards
nstitute (CLSI) published M53-A, Criteria for Laboratory Testing
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; HIV, human
mmunodeﬁciency virus; APHL, Association of Public Health Laboratories; CDC,
enters for Disease Control and Prevention; EIA, enzyme immunoassay; WB,  West-
rn  blot; Ab, antibody; Ag, antigen; NLHRS, National Laboratory for HIV Reference
ervices; N/T, not tested; Pos, positive; Ind, indeterminate; GS, genetic systems;
IPA, radioimmunoprecipitation assay; LSR, lab-speciﬁc report; FDA, Food and Drug
dministration; CE, European conformity; Inno-LIA, INNO-LIA HIV I/II score; PCR,
olymerase chain reaction; DNA, deoxyribonucleic acid; RNA, ribonucleic acid.     
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and Diagnosis of Human Immunodeﬁciency Virus (HIV) Infection;
Approved Guideline.1 This guideline was a joint effort over two
years with expertise from different backgrounds including the Cen-
ters for Disease Control and Prevention (CDC), the Association of
Public Health Laboratories (APHL), CLSI and industry.2 It repre-
sents the most signiﬁcant contribution to HIV testing since the
1989 guideline in which a repeatedly reactive sample by a screening
immunoassay, was to be conﬁrmed by a supplemental HIV antibody
(Ab) test, usually the Western blot (WB) or the indirect immuno-
ﬂuorescence assay.3
Although M53-A contains 6 unique algorithms addressing a
range of HIV testing scenarios, Algorithm I (Fig. 1) has generated
considerable interest and is likely to have the biggest impact on
routine HIV testing. Algorithm I contains three categories of tests;
(i) 4th generation HIV Ab and antigen (Ag) combo assay, (ii) HIV-
Open access under CC BY license.1/HIV-2 discrimination assay and (iii) Nucleic acid testing. One
unique feature of this new algorithm is the absence of the HIV-1 WB.
Validation data has revealed the shortest HIV diagnostic window
period thus far.4,5
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Panel HIVS425-2012Nov22, sent by the National Laboratory
or HIV Reference Services (NLHRS) to forty-two Canadian labo-
atories was designed to address the impact of M53-A Algorithm
 and challenge the wide-ranging tests and algorithms used in
anada.
. Methods
.1. Samples
Panel HIVS425-2012Nov22 contained ﬁve samples (Table S1);
ne HIV negative (B) and four HIV positive (A, C, D and E) (Dis-
overy Life Sciences, CA; Seracare Life Sciences, MA)  and were
xtensively characterized (Table S1, Fig. S1). Samples A and E were
nti-HIV-1 Ab positive, sample C was anti-HIV-2 Ab positive and
ample D was HIV-1/2 Ab negative-HIV-1 Ag positive. Panels were
istributed to 42 laboratories under similar conditions to clinical
amples.
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jcv.2013.04.009.
.2. Laboratories, testing and data entry
Algorithms and tests range from single screen-only to con-
rmatory (Table S2, Fig. S2). Panels were shipped November
th 2012; the closing date for data entry was November 22nd
012. Results were entered using DigitalPT (Vancouver, BC); an
n-line tool for standardized data entry, collation and group
nalysis. Group data was analyzed by the NLHRS for the ﬁnal
eport.
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jcv.2013.04.009.ds Institute M53-A algorithm I.1
3. Results
Results were returned from 98% of laboratories (41/42) by the
deadline to be included in the group analysis. The remaining 41
laboratories’ diagnosis for each sample is listed in Table S3.
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jcv.2013.04.009.
3.1. Samples A, B and E
All laboratories correctly identiﬁed these three samples. All but
two laboratories made an appropriate ﬁnal serology status or rec-
ommendation based on their algorithms.
3.2. Sample C (HIV-2 Ab positive)
Of 41 laboratories, ‘none’ correctly diagnosed sample C as HIV-2
Ab positive. One laboratory provided no ﬁnal status or recommen-
dation to refer the sample to a reference or provincial laboratory
or request a follow-up sample for further testing. Three laborato-
ries did not provide a ﬁnal status, only making a recommendation.
Although thirty-two laboratories (78%) identiﬁed this sample as
either HIV-1 Ab positive (4), HIV-1/2 Ab positive (9) or HIV-1/2
Ab/Ag positive (19), a recommendation was made. Five laborato-
ries (12%) made no recommendations; one identiﬁed the sample as
indeterminate while the other four identiﬁed the sample as HIV-1
Ab positive. All ﬁve used the HIV-1 WB  for conﬁrmatory testing.
The algorithm of one of those four laboratories included an HIV-2
EIA in addition to an HIV-1 WB,  but they still identiﬁed the sample
as HIV-1 Ab positive although their HIV-2 screen test was reac-
tive.
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.3. Sample D (HIV-1/2 Ab negative-HIV-1 Ag positive)
Two laboratories (5%) correctly identiﬁed this sample as HIV-1
g positive but also incorrectly identiﬁed it as HIV-1 Ab positive
lthough the conﬁrmatory Ab test was negative. Three laboratories
7%) did not provide a ﬁnal status and only made a recommen-
ation. Twenty-nine laboratories (71%) reported a wide range of
IV reactivities however they all made recommendations promp-
ing further testing. Six laboratories (15%) identiﬁed this sample as
IV-1/2 Ab negative with no further recommendations.
. Discussion
.1. What would happen if a laboratory received an HIV-2
ample?
‘None’ of the Canadian laboratories were able to distinguish
ample C as HIV-2 Ab positive. All laboratories, however, reported
ome level of reactivity with the majority making a recommen-
ation. Four laboratories (10%) reported the sample as HIV-1 Ab
ositive with no further recommendations.
The majority of HIV screening assays allow for the detection of
IV-1/2 however, there are no approved conﬁrmatory assays for
he discrimination of HIV-2 in Canada. Although cross reactivity on
he HIV-1 WB  often occurs (Fig. S1), it may  lead to an ‘indetermi-
ate’ result or a false diagnosis of HIV-1 positivity. The absence of
ross reactivity can occur, resulting in a false-negative diagnosis
internal validation-NLHRS). Even if laboratories referred an HIV-2
b sample to a provincial or reference laboratory, it is unlikely these
eferral laboratories would have had the ability to discriminate HIV-
. In the United States there is currently one FDA approved assay,
hich discriminates between HIV-1 and HIV-2 (Bio-Rad HIV-1/2
ultispot). The NLHRS has employed the CE-labeled Innogenet-
cs INNO-LIA HIV I/II Score (Inno-LIA) for over 10 years, which can
iagnose and discriminate HIV-2. The NLHRS also uses an in-house
IV-2 speciﬁc PCR leading to a comprehensive ability to diagnose
nd discriminate HIV-2 and HIV-1. In Canada, unlicenced assays
uch as the Inno-LIA must be obtained through the Special Access
rogram.
.2. What would happen if a laboratory received an HIV-1 Ab
egative-Ag positive sample?
The majority of laboratories that used fourth generation assay
etected sample D and made a recommendation. Four laborato-
ies (10%) reported this sample as HIV-1 Ab negative but made
 recommendation. These labs used an HIV-1/2 Ab screen test
nly and it is likely their algorithm takes into consideration that
 pre-seroconversion sample, similar to sample D could be missed,
rompting further testing.
It is alarming that six laboratories (15%) incorrectly identiﬁed
ample D as HIV-1/2 Ab negative with no further recommen-
ations, identifying limitations and weaknesses in their current
lgorithms to detect pre-seroconvertors or acute infection leading
o the potential of patients being misdiagnosed as false-negative
or HIV. None of these laboratories used a 4th generation (combo)
IV EIA, with most (4/6) still using a 3rd generation HIV-1/2 EIA.
he inability to detect these early acute infections and their impact
n public health is obvious.. Conclusion
The publication of the CLSI M53-A HIV testing guide-
ine is anticipated to have a major impact in industrialized
7 Virology 58 (2013) 303– 305 305
countries. Utilizing the latest technology, it addresses several
weaknesses in current testing, including the inability to (i)
discriminate HIV-2 and (ii) diagnose acute phase infections (pre-
seroconvertors).
There is controversy surrounding this new guideline. A 2012
survey conducted by the APHL revealed cost, workforce/regulatory
requirements and remarkably, ‘a lack of perceived need’ as
impediments.6 While preliminary data demonstrates the cost
effectiveness of implementation, the survey revealed replace-
ment of the WB would likely prove challenging.6,7 The majority
of public health laboratories cited the lack of a formal recom-
mendation from the CDC as a major barrier to discontinuing
the use of the WB  in favor of an HIV-1/HIV-2 discrimination
assay.6 Considering that very little has happened since the orig-
inal HIV testing guideline in 1989, it is not surprising that
end clients, namely clinicians, and laboratorians will need to
be educated on new tests and their use in this new algo-
rithm.
Panel HIVS425-2012Nov22 demonstrated deﬁciencies still exist
and improvements need to be made. The M53-A guideline should
aid to ensure the highest quality of HIV testing in Canada
allowing better diagnosis of HIV-2 infections and early HIV-1 infec-
tions.
Funding
The National Laboratory for HIV Reference Services is funded by
the Federal Initiative to Address HIV/AIDS in Canada – Public Health
Agency of Canada.
Competing interests
None declared.
Ethical approval
Not required.
Acknowledgements
The authors would like to acknowledge the Canadian par-
ticipants of the NLHRS HIV proﬁciency testing program and
HealthMetrx, Vancouver, British Columbia. We  also acknowledge
the excellent technical assistance and reading by Barb Calder-
Kent.
References
. Clinical and Laboratory Standards Institute (CLSI). Criteria for Laboratory Testing
and Diagnosis of Human Immunodeﬁciency Virus Infection; Approved Guide-
line. CLSI document M53-A (ISBN 1-56238-757-X [Print]; ISBN 1-56238-758-8
[Electronic]); 2011.
. CDC. Notice to readers: publication of HIV testing algorithms: a status report.
MMWR 2009;58(30):830–1.
. CDC. Interpretation and use of the Western blot assay for serodiagnosis of human
immunodeﬁciency virus type 1 infections. MMWR  1989;38(S-7):1–7.
. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM.
Evaluation of an alternative HIV diagnostic algorithm using specimens from
seroconversion panels and persons with established HIV infections. J Clin Virol
2011;52S:S17–22.
. Styer LM,  Sullivan TJ, Parker MM.  Evaluation of an alternative supplemental test-
ing  strategy for HIV diagnosis by retrospective analysis of clinical HIV testing data.
J  Clin Virol 2011;52S:S35–40.Brief;  2012. p. 1–12.
. Hutchinson A, Ethridge S, Wesolowski L, Farnham P, Shrestha R, Patel P, Branson
B.  Cost and effects of the APHL/CDC proposed laboratory-based algorithm for the
detection of HIV. In: 2012 HIV Diagnostics Conference. 2012 [oral presentation].
